Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Marvin KuskeFriedegund Meier

Abstract

Targeted therapy with BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provides rapid disease control with high response rates in patients with BRAF-mutant metastatic melanoma. However, the majority of patients develop resistance to therapy during the course of therapy. Immune checkpoint inhibitors show a slower onset of action with lower response rates, with responders showing sustained response. The combination of BRAFi/MEKi and immune checkpoint inhibitors combines the hope for a fast, reliable and lasting response to therapy. Preclinical data supports this hypothesis. With the help of the PubMed database, a comprehensive search and analysis of preclinical and clinical studies on the combination of BRAFi/MEKi with immune checkpoint inhibitors was performed and yielded the following results: 1) In vivo, BRAFi and MEKi have no negative effects on immune cells; BRAFi and MEKi generate 2) an immune stimulating tumor microenvironment, 3) an increased infiltration of immune cells into the tumors, 4) a better recognition of melanoma cells by immune effector cells, and 5) a better functionality of the immune effector cells. In addition, in vivo experiments 6) demonstrated a superiority of the combination treatment compared to the i...Continue Reading

Citations

Jul 10, 2019·Expert Opinion on Therapeutic Patents·Peng-Fei WangHai-Liang Zhu
Jan 18, 2020·Journal of Clinical Medicine·Frank Friedrich GellrichFriedegund Meier
Jul 11, 2020·Cancers·Ilaria ProiettiConcetta Potenza
Jun 6, 2020·Future Oncology·Maria Virginia BluthgenGonzalo Recondo
Nov 22, 2019·Frontiers in Oncology·Marco TucciFrancesco Silvestris
Mar 22, 2020·Current Oncology Reports·Nalan Akgul Babacan, Zeynep Eroglu
Jul 31, 2019·Seminars in Cancer Biology·Maria Rosaria RuoccoAlessandro Arcucci
Feb 19, 2021·Frontiers in Immunology·Samuel I KimKatelyn T Byrne
Apr 4, 2021·International Journal of Molecular Sciences·Margaret Ottaviano On Behalf Of Scito Youth
Apr 4, 2021·Cancers·Julian SteiningerFriedegund Meier
Oct 20, 2019·Annales de dermatologie et de vénéréologie·E RohmerC Lenormand
May 4, 2021·Frontiers in Pharmacology·Yuanqi LiuChunfang Zhang
Jul 25, 2021·International Journal of Molecular Sciences·Marcella TazzariViviana Vallacchi
Jul 7, 2021·The Oncologist·Nalan Akgul BabacanZeynep Eroglu
Jul 12, 2021·Neoplasia : an International Journal for Oncology Research·Haris BabačićMaria Pernemalm
Jul 27, 2021·Journal of Investigative Medicine High Impact Case Reports·Christopher C HemondKeith R Edwards
Aug 27, 2021·Molecular Cancer Therapeutics·Paul RossmanDeborah W Knapp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Zachary A CooperJennifer A Wargo
Handbook of Experimental Pharmacology
Mario Mandalà, Daniela Massi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Chengwen LiuPatrick Hwu
© 2022 Meta ULC. All rights reserved